top of page


Wednesday, September 14th, 2022

08:30 // Registration and coffee

09:00 // Welcome

09:15 // SESSION 1: Will molecular tests enable sustainable precision medicine? 

               Chair: Kristin Austlid Taskén, Oslo University Hospital (NO)

09:15 // Genomics/PARP-I in Prostate Cancer: What, when and who

              Maha Hussain, Northwestern University Feinberg School of Medicine (US)

09:45 // Will biomarkers - other than PSA - be used to guide treatment of advanced prostate cancer?

              Nicolas Mottet,  University Hospital St. Etienne and University Jean Monnet  (FR)

10:15 // How cost-effective are biomarkers?

              Derya Tilki, Martini-Klinik Prostate Cancer Centre, Hamburg (DE)

10:45 // The biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C, and 

              possibilities for their clinical implementation (selected from submitted abstracts)

              Pernilla Wikström, Umeå University, Umeå (SE)

11:00 // Break

11:30 // SESSION 2: Providing evidence for implementing molecular tests in clinical guidelines

              Chair: Rolf Skotheim, Oslo University Hospital (NO)

11:30 // Requirements for implementation of molecular tests into guidelines

              Himisha Beltran, Dana-Farber Cancer Institute and Harvard Medical School (US)

              Dentist Olaf Aase and wife memorial lecture

12:00 // Extracellular vesicles - from lab to clinical implementation

              Jason M Alter, Exosome Diagnostics (US)

12:30 // Cribriform growth pattern with a high Ki-67 represents a subgroup of prostate cancer patients with a

              particularly poor prognosis (selected from submitted abstracts) 

              Ulrika Axcrona, Oslo University Hospital, Oslo (NO) 


12:40 // Spatial transcriptomics reveals biomarker SFRP4 to be strongly associated with extracellular matrix

              remodeling in prostate cancer stroma (selected from submitted abstracts)

              Maria Karoline Andersen, Norwegian University of Science and Technology, Trondheim (NO) 

13:00 // Lunch

14:00 // Biomarker-driven precision medicine in Norway - where we are and where to go

              Hege Russnes, Oslo University Hospital (NO)

14:15 // How to bring molecular tests into the clinic in Scandinavia

              Henrik Grönberg, Karolinska Institutet and Capio S:t Göran Hospital (SE)

14:45 // Break

15:00 // Panel Discussion (in Norwegian)

              - How and when can molecular tests provide sustainable precision medicine in the clinic?

              Moderator Elisabeth Kirkeng Andersen (NO)

16:00 // Poster session

17:00 // Social activities (Munch museum, sauna, walk)

19:30 // Dinner (including Poster Awards) at Vaaghals

Thursday, September 15th, 2022

09:00 // SESSION 3: Precision medicine: impact of the tumour microenvironment 

              Chair: Heidi Lyng, Oslo University Hospital (NO)

09:00 // Everything in balance? Metabolism reprograms cells

              Ian Mills, University of Oxford, Queen’s University of Belfast and University of Cambridge (UK) ​

09:30 // Hypoxia and subclonal evolution 

              Rob Bristow, Manchester Cancer Research Centre, CRUK Major research Centre, University of Manchester (UK)

10:00 // How can we move forward with immunotherapy in prostate cancer?  

              Johanna Olweus, Oslo University Hospital (NO)

10:15 // Break

10:45 // Discovery and testing of biomarkers and drugs in ex vivo and in vivo model systems

              Wytske van Weerden, Erasmus Medical Center (NL)

11:15 // Biomarker potential of tumor hypoxia

              Heidi Lyng, Oslo University Hospital (NO)

11:30 // Lunch 

12:30 // Reversing off-target prostate cancer resistance

              Mark Rubin, University of Bern (CH)

13:00 // Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1

              Retrotransposition as a Dynamic Source of Cancer Heterogeneity (selected from submitted abstracts)

              Kirsi Ketola, University of Eastern Finland, Kuopio (FI)

13:10 // Phenotypic deconvolution in heterogeneous cancer cell populations using drug screening data

              (selected from submitted abstracts)

              Even Moa, University of Oslo, Oslo (NO)

13:20 // SESSION 4: Pitfalls and opportunities in biomarker discovery

              Chair: Alicia Llorente, Oslo University Hospital (NO)

13:20 // Functional and spatial precision cancer medicine

              Olli Kallioniemi, Karolinska Institutet (SE)

13:50 // Break

14:20 // Exploring precision oncology: From gene fusions to lncRNAs

              Arul Chinnaiyan, Michigan Center for Translational Pathology and Howard Hughes Medical Institute (US)

14:50 // Multifocal prostate cancer and implications for precision oncology

              Rolf Skotheim, Oslo University Hospital (NO)

15:05 // Analysis of urinary extracellular vesicles form the discovery of prostate cancer biomarkers

              Alicia Llorente, Oslo University Hospital (NO)

15:20 // European network for biomarker validation

              Guido Jenster, Erasmus Medical Centre (NL)


16:00 // Closing remarks



bottom of page